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Purpose:  The problem of fake and counterfeit drugs is real and constitutes a major threat to the health 
and safety of the Nigerian population. A descriptive study was carried out to assess the methods of 
identification of counterfeit drugs by community pharmacists in Lagos State. 
Methods:  The research instrument was a 23-item questionnaire, which was administered to consenting 
community pharmacists in 17 out of the 20 Local Government Areas in Lagos State. 
 A convenient sample of practicing community pharmacists both in retail and wholesale distribution of 
pharmaceutical products were recruited into the study using a list of registered pharmacists from the 
Association of Community Pharmacists in Lagos State. Effort was made to ensure adequate 
representation of Pharmacies in every local government area in Lagos State. 
Results All the respondents agreed that there is a fake and counterfeit drug problem in Nigeria, and 
(74%) considered this a major problem. The respondents commonly used visual security techniques 
before drug purchasing. These were: Seals/embossments (83%), character of print (77%), and 
Holograms (68%).The respondents’ most likely action after a counterfeit drug encounter was to return 
the drug back to the supplier. 
Conclusion: The study showed that pharmacists sampled were aware of the prevalence of fake and 
counterfeit drugs and quite a number of them have had encounters with them. There is an indication that 
the respondents try to assure themselves of the quality of the drugs they purchase by use of several 
methods. However, no rigorous effort was taken to confirm as well as report suspected fake and 
counterfeit drugs to regulatory authorities. 
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INTRODUCTION 
The problem of fake and counterfeit drugs exists 
in both developed and developing countries. 
From January 1999 to October 2000, the World 
Health Organisation (WHO) received 46 
confidential reports of counterfeit drugs from 20 
countries. Of these, 60% came from developing 
countries. (1) Counterfeiting of drugs has become 
highly profitable and counterfeiters have 
seriously improved on their cloning of genuine 
drugs because of recent technological advances  
A counterfeit drug is one, which is deliberately, 
fraudulently mislabelled with respect to identity 
and or source. (2) Counterfeiting could be in the 
form of insufficient amounts of ingredients, 
incorrect ingredients, lack of active ingredients 
or fake packaging. 
In Nigeria, the National Agency for Food and 
Drug Administration and Control (NAFDAC) has 
enlarged the scope of counterfeit drugs to 
include drugs without the full name and address 
of manufacturers, drugs labelled “For Export 
Only”, expired and relabelled drugs with the 
intention of extending their shelf lives, drugs 
containing banned substances and drugs not 
registered by NAFDAC. (3)
The World Health Organisation (WHO) has 
estimated that 10% of global pharmaceutical 
commerce is in counterfeit drugs and is present 
in all countries. (4, 5, 6) Informed estimates put the 
size of the annual global market in fake drugs in 
the region of USD30 billion, which represents 
about 7% of pharmaceutical industry revenue. 
(7,8)    A survey of pharmacies in the Philippines 
showed that 8% of drugs bought were fake, 
another survey done in five countries in 
mainland South East Asia reported that 40% of 
tablets sold as the new antimalarial Artesunate 
were fake. (8,9)    
 
Pharmacists are the custodians of drugs and 
have the responsibility for sourcing, 
manufacturing, distributing, dispensing and 
monitoring the outcome of drug therapy on 
users.  Sadly, this is strictly not so in the 
Nigerian context where drug distribution is 
chaotic and has become an all-comers affair.  
Pharmacists find themselves in the same 
situation as the members of lay public who have 
no clue whether the drug they have purchased is 
genuine or fake. 
To our knowledge, there has been no study 
carried out to investigate how pharmacists, 
particularly in the community setting identify or 
differentiate between genuine and fake / 
counterfeit drug products. 
The objectives of this study were to: determine 
the frequency of fake and counterfeit drug 
experiences; identify the most common methods 
of identifying such drug products; assess the 
use of visual clues in identification of fake and 
counterfeit drugs and to determine likely action 
following the detection of counterfeit drugs by 




Data was collected for this study from 17 out of 
the 20 statutory local government areas (LGAs) 
in Lagos State.  The sample was chosen to 
represent the spread of community pharmacists 
registered in Lagos State.  Lagos Island, Ipeju-
Lekki and Epe were excluded due to non-
availability of pharmacists in those areas. 
Lagos State was selected because it is the 
major distribution centre for imported 
pharmaceutical products and has the largest 
concentration of pharmaceutical manufacturers, 
as well as community pharmacists in Nigeria. 
 
SAMPLE 
A convenient sample of 69 practicing community 
pharmacists, both in retail and wholesale 
distribution of pharmaceutical products were 
recruited for the study, using a list of registered 
pharmacists from the Association of Community 
Pharmacists in Lagos State as the sampling 
frame. From this list, a simple random selection 
procedure by use of a ballot was done per LGA, 
in order to ensure adequate representation of 
pharmacies in every LGA in the state. 
 
Questionnaire design and administration 
The research instrument had two sections. 
Section A was designed to elicit demographic 
information of the respondents such as age, 
location, type of pharmacy and number of years 
in practice. Section B was made up of 17 
questions, some of the questions required a 
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simple Yes or No response e.g. “I have had an 
experience stocking fake and counterfeit drugs 
in my pharmacy”, “I usually procure drugs for my 
pharmacy”, “I check on the source of drugs 
before procurement”, “I have reported a case of 
fake and counterfeit drugs to the regulatory 
authorities”  “Nigeria has a fake and counterfeit 
drug problem”. The responses to a few 
questions were anchored on an ordinal scale 
e.g. for the question “I would classify my 
experiences of fake and counterfeit drugs as 
being:”options were very often, often, seldom 
and none. The respondents were asked in 
another question to classify the fake and 
counterfeit drug problem in Nigeria as: major, 
moderate, minor or none. 
 
The remaining questions focused on other 
objectives of the study such as; the methods 
employed by respondents to detect fake drugs, 
factors that determine where they source their 
drugs, their most frequent sources of drug 
procurement, visual and regulatory security 
marks that guided their drug purchases  as well 




 Data was entered into EPI Info version 6 and 
descriptive statistics were computed for all 




Overall, 100 copies of the questionnaire were 
distributed to the community pharmacists and 69 
completed usable questionnaires were received, 
giving a response rate of 69%. 
About two – thirds of the respondents 65.2% 
(45/69) were males, majority of the respondents 
73.3% were aged between 31 – 50 years, with a 
mean age of 41.7 years.  Most of the 
respondents 57, (82.6%) were in retail practice, 
while only 12 (17.4%) were in wholesale 
practice.  Only 21.7% of them had additional 
qualifications.  The mean period of practice 
experience was 17.3 years. 
 
All the respondents agreed that Nigeria has a 
fake and counterfeit drug problem; 51 (74%) of 
the respondents went further to describe the 
problem as major. The remaining 18 (26%) 
thought it was moderate. Some 59 (86%) of the 
respondents procured their drug products 
personally, while 10 (14.5%) were not personally 
involved in drug procurement. 52 (75%) of 
respondents sourced their drugs from 
middlemen and drug wholesalers. Other sources 
were the “open markets” and pharmaceutical 
company representatives, (Table 1). Fifty-six 
(81%) of the respondents agreed that they 
checked on the source of their drugs before 
procurement. The factors that determined where 
respondents made their purchases included the 
reputation of the distributor (62%) and a 
personal good feeling that the product is 
genuine (41%). Others are as shown in Table 1. 
 
About 42 respondents (61%) had experienced 
stocking some counterfeit products in their 
premises. Scrutiny of purchased drug products 
was indicated as the commonest means of 
screening for fake and counterfeit drugs by 51% 
of respondents. Other methods were customers’ 
complaints (10.1%) and alerts from 
pharmaceutical companies (7.3%). No 
respondent reported ever receiving any help 
from regulatory officials in detecting fake and 
counterfeit drugs. 
The visual security guides used by respondents 
included seals and tablet embossments, which 
had the highest guide rate (83%), this was 
followed by character of print (77%). 
 Other methods such as holograms, colour of 
package and colour of product were also used 
but to a relatively less extent.  
As regards detecting fake drugs by use of 
regulatory markings on drug packaging,   
majority (83%) of the respondents checked for 
NAFDAC registration numbers while 
manufacturers’ name/address and expiry/date of 
manufacture of drug were checked by 71% and 
69% of respondents respectively. The check for 
batch number was the least and was done by 
only about 39% of respondents 
 
Fifty-six (81%) of the respondents had never 
reported any case of fake and counterfeit drug 
encounter to the regulatory authorities. The most 
likely action of the respondents after an 
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Table I: Responses to issues relating to drug sourcing and counterfeit drug detection. 
                              Frequency (%)a
Methods of detecting fake drugs by respondents 
      Customers                                                                                                       7                 10.1 
      Close scrutiny                                                                                                35                50.7  
      Regulatory officials                                                                                        0                  0 
      News/company alerts                                                                                     5                   7.3 
      No response                                                                                                   28                 40.6  
Determinants of where to source drugs  
       Good feeling                                                                                                  28                40.6 
        Distributor                                                                                                    43                62.3 
        Medical Representative                                                                                32                46.4 
        References from other pharmacists                                                              14                20.3  
Most frequent source of drug procurement  
         Open market                                                                                                11                15.9 
         Medical representative                                                                                39                56.5 
         Middle men/ Wholesalers                                                                           52                75.4   
Visual security checks which guide respondent’s purchases 
         Holograms                                                                                                   47                68.1  
         Seals/Embossments                                                                                     57                83.0 
        Character of print                                                                                         53                 77.0 
        Colour of package                                                                                        42                61.0 
        Colour of drug product                                                                                 41                59.4 
        No response                                                                                                    4                 5.8  
Regulatory marks that guide respondent’s purchases 
         NAFDAC number                                                                                       60                87.0 
          Batch number                                                                                             27                39.1 
          Manufacturers’ name address                                                                    49                71.0 
          Date of manufacture/Expiry                                                                       48                69.0 
          No response                                                                                                  2                 2.9 
                                            
 
a multiple responses were allowed hence total above 100%. ncounter included ‘taking the product back to 
he supplier’ (65.2%), ‘reporting to professional 
odies’ (50.7%), ‘taking the product back to its 
istributor’ (11.6%), and ‘reporting to NAFDAC’ 
18.8%). A few of the respondents (11.6%) did 
ot respond. 
esults of the assessment of the impact of 
AFDAC at curbing the proliferation of 
ounterfeit drugs showed that 18.8% of the 
espondents thought they were very effective; 
ut the majority (63.8%) thought they were only 
oderately effective while 15.9% thought they 
ere ineffective. 
DISCUSSION 
The problem of fake and counterfeit drugs is 
widespread with a high global prevalence. 
Reports from the pharmaceutical industry and 
governments clearly indicate that the methods 
and channels used by counterfeiters are now 
more sophisticated, thus making counterfeit 
medicines difficult to detect. (4, 10, 11, 12)
This survey shows that majority of the 
respondents have experienced stocking some 
counterfeit drug products in their premises. The 
common means by which they screen for 
phoney products was by close visual scrutiny. 
This finding is very encouraging as it suggests 
that the respondents are aware of the high 
occurrence of fake drugs and are motivated to 
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check for drug security measures in order to 
identify such products. However, it is pertinent to 
note that fake and counterfeit drug detection 
using only visual inspection is not foolproof and 
so is unreliable except when the suspected drug 
is from unsophisticated forgers.  
All the respondents agreed that Nigeria has a 
fake and counterfeit drug problem and majority 
of them described this problem as being major. 
This is consistent with findings in several 
publications. (7, 8, 10)
 
Another interesting finding in this survey is the 
fact that majority of the respondents claimed 
they sourced their drug products personally from 
wholesalers. This is quite cheering considering 
the fact that only few of the respondents 
patronized the open drug markets, which has 
become a singular major source of 
pharmaceutical products in Nigeria. However, 
there is a worrying concern about where the 
wholesalers get their products. There is proof 
that major pharmaceutical distributors and even 
medical representatives dump their products in 
unlicensed open markets in order to meet sales 
targets and make quick turnover (4, 10)
 
It is commendable that majority of the 
respondents are critical of the sources of drugs 
before procurement, but the factors that 
determine where they eventually make 
purchases is not so laudable.  This survey 
revealed that the determinants as to choice of 
sources of purchase include the reputation of 
supplier and the purchasing pharmacist’s “good 
feeling” that the products carried by the source 
are genuine. Some of these determinants as 
reported by the respondents are highly 
subjective and are based on the respondent’s 
experience.  
As regard regulatory marks, NAFDAC 
registration number, manufacturer’s name/ 
address were the most commonly checked 
regulatory marks before drug purchase by 
respondents. The product batch number was the 
least checked regulatory mark on drug products. 
The reason for this was taught to be that a batch 
number in itself does not protect against 
purchasing fake and counterfeit drugs except of 
course when there is a ridiculous large quantity 
of the same batch number or when there has 
been an alert that drugs with a particular batch 
number are fake (13)
 
NAFDAC registration number on drug products 
accounted for the highest regulatory mark check 
rate by the respondents, this is not surprising 
because in Nigeria, product registration leads to 
the issuance of a NAFDAC number which is an 
administrative tool used in the limiting the 
number and types of regulated, imported or 
manufactured drugs in the country.  It also aids 
in the introduction of new products as well as 
removal of unsuitable products from the market. 
The presence of NAFDAC number is part of the 
climax of all built in processes designed to 
ensure that drugs are safe, efficacious and of 
good quality.  Therefore the reliance on 
NAFDAC number, as a security guide by 
respondents is praiseworthy.  However, these 
numbers have been known to be faked and so it 
behoves the regulatory Agency to intensify and 
regularly inspect drug outlets in the country, in 
order to identify and publicize such products.  
 
This study reveals that only few of the 
respondents have ever reported a case of fake 
and counterfeit drug to the authorities. This is 
disheartening considering the fact that majority 
of the respondents have had encounters with 
fake and counterfeit drug products in their 
practices. The preferred action of the 
respondents after an encounter was to return 
the fake product to the supplier rather than 
making a report to the regulatory authorities or 
destroying the product. This action prevents any 
possible arrest or prosecution of the culprit as 
well as encourages subsequent redistribution of 
the product. It is believed that the respondents 
prefer to return suspected spurious products to 
suppliers because, this way, they are not likely 
to lose the capital invested in such purchases, 
unlike when they choose the alternative of 
reporting or destroying the suspected products. 
Furthermore, majority of respondents in this 
study assessed NAFDAC’s activities at curbing 
the proliferation of fake and counterfeit drugs as 
only moderately effective this may also be a 
factor why majority of the respondents do not 
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collaborate with NAFDAC after a fake and 
counterfeit drug encounter. 
 
LIMITATIONS 
The use of a convenient sample of pharmacists 
in Lagos state would limit the extent to which the 
study sample was representative of the opinions 
and practices of the general population of 
pharmacists at large. Also non-respondent data 
were not collected and therefore no 
characterizations can be made about them.  
 
CONCLUSION 
Pharmacists sampled are aware of the high 
prevalence of fake and counterfeit drugs and 
quite a number of them have had encounters 
with them. There is an indication that the 
respondents try to assure themselves of the 
quality of the drugs they purchase by use of 
several methods. However, no rigorous effort 
was taken to confirm as well as report suspected 
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